The company is focused on a digital-first marketing approach, increasing its share of digital spend from approximately 44% in 2019 to 73% in 2023. This shift has enabled flexibility and efficient reach to high-value audiences.

Kenvue's R&D organization combines scientific expertise with healthcare professional engagement and places human empathy at the heart of product development. They leverage extensive capabilities and consumer insights to drive innovative products and solutions.

Kenvue aims to leverage its flexible distribution network and data-driven customer partnerships to drive value creation for retail customers. The company operates in more than 165 countries with approximately half of net sales generated outside of North America.

Kenvue is continuously modernizing its supply chain operations while connecting with and serving customers. They have a digitally-connected supply chain ecosystem designed to optimize flexibility and agility.

The company has a strong culture of quality across its organization, enhanced by rigorous compliance procedures. They have invested in quality systems and data analytics to drive proactive quality management.

Kenvue launched an update to its Healthy Lives Mission in October 2023 with public ESG goals and commitments. They are focused on nine priority areas within three pillars: nurture Healthy People, enrich a Healthy Planet, and maintain Healthy Practice.

The company faces substantial competition from various sources, including multinational corporations, smaller regional companies, private-label brands, and generic non-branded products, which could adversely affect their business, results of operations or financial condition.

Kenvue relies on third parties for manufacturing, supply, distribution, and other aspects of its business, which involves a lesser degree of control over business operations, compliance matters, cybersecurity and ESG practices.

The company faces legal proceedings related to talc or talc-containing products sold outside the United States and Canada, which could result in significant expenses, liabilities, and reputational damage. J&J has agreed to indemnify Kenvue for certain talc-related liabilities for products sold in the United States and Canada.

Kenvue competes with a broad set of competitors, including consumer healthcare businesses, global CPG companies, regional companies, generic OTC manufacturers, and emerging niche-oriented brands.

The company's portfolio includes iconic, trusted brands that are leaders in their respective categories and some of the most recognizable household names across the industry.

The company expects that the continued attractiveness of its categories and geographic markets will encourage the entry of new competitors, which could increase competitive pressures.

The company is continuously modernizing its supply chain operations while better connecting with and serving customers. The end-to-end, digitally connected supply chain ecosystem is designed to optimize flexibility and agility.

Kenvue's in-house manufacturing footprint delivers over half of its production volume, with the remaining volume supplied by an extensive network of external manufacturing facilities, providing significant operational flexibility.

The company has a strong culture of quality across its end-to-end organization, enhanced by rigorous compliance procedures, and invests in quality systems and data analytics platforms.

Kenvue's marketing approach is centrally focused on the consumer and leverages insights across product offerings. They are a digital-first modern marketing company, with 73% of media spend in digital channels.

The company's R&D organization operates a global footprint of innovation hubs located close to consumers in key geographic markets, with a team of 1,500 scientists, doctors, pharmacists and engineers.

Kenvue offers connected health offerings, including digital diagnostics and telemedicine, to expand personalized solutions to consumers.

The company's Board authorized a share repurchase program to repurchase up to 27 million shares of outstanding common stock. The program has no expiration date and may be suspended or discontinued at any time.

The company has declared a quarterly cash dividend of $0.20 per share of common stock, demonstrating a commitment to returning capital to shareholders.

The company has utilized debt financing, including senior notes and a commercial paper program, to fund operations and distributions related to the separation from J&J.

The company updated its Healthy Lives Mission in October 2023, which includes public ESG goals and commitments, intended to position brands as healthy choices for people and the planet and to better manage ESG-related impacts, risks, and opportunities.

Kenvue's Healthy Lives Mission is supported by three pillars: nurture Healthy People, enrich a Healthy Planet, and maintain Healthy Practice, with a focus on nine priority areas.

The Board of Directors is ultimately responsible for independent oversight of ESG impacts, risks, and opportunities. Oversight for ESG, sustainability and reporting is allocated across all three key Committees of the Board.

The company is exposed to global economic challenges, including the impact from acts of war, military actions, terrorist attacks, or civil unrest, which may cause economic uncertainty and volatility.

The company is impacted by the rapidly changing retail landscape, including the increasing dependence on key retail trade customers, changes in customer policies, and the emergence of e-commerce and other alternative retail channels.

The company is subject to extensive government regulations in the United States and around the world, and the global regulatory landscape is subject to rapid and unexpected changes.